click

Alcon Science | United States

This page is available in English. Select below for other countries.

Select other country

MEDICAL EDUCATION

Post Graduate Specialized Grant

Eligibility Process

All requests for Postgraduate Specialized Grants must be submitted in writing by the requesting organization directly to Alcon via the submission portal. To determine eligibility for a Postgraduate Specialized Grant from the Independent Medical Education Grant Office (IME), please complete the online Eligibility Questionnaire.

 

Image of an elderly man

Guidelines, Requirements, and Next Steps

Guidelines

 

Please note the following general guidelines for Postgraduate Specialized Grants: 

Requesting organization must be tax exempt or government affiliated

  • Organization should be an accredited ophthalmology program (ACGME)
  • Requests are limited to one grant per university for each academic year 

 

Requirements

 

The submission must include the following information about the organization:

  • Organization’s name, address, and phone number that coordinates with the Form W-9 (for US institutions) or with the Certificate of Incorporation or Certificate of Existence (for Canadian institutions)
  • Lead contact at requesting organization with phone number and email address for follow-up
  • Letter of Request on the school’s letterhead signed by the chair

 

Note: The submission must include Program Budget, Course Syllabus, Educational Objectives, and a Post-Event Outcomes Measurement Plan

 

Next steps

 

  • Request is reviewed by the IME Grant Office
  • Notification of whether request will be accepted for consideration will be provided within 5 business days

 

Accepted requests will remain active unless notified otherwise by requesting party

 

Recent Scientific Publications

 

 

DRY EYE

 

AR-15512 Registration Clinical Studies

 

 

 

DRY EYE

 

A Review of Phase 3 Trial Results for Acoltremon (AR-15512) Ophthalmic Solution 0.003%

 

 

DRY EYE

 

AR-15512: Results of Phase 3 Studies for Acoltremon Ophtalmic Solution 0.003%, a Novel TRPM8 Agonist